Joycelyn Sim

587 total citations
19 papers, 292 citations indexed

About

Joycelyn Sim is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Joycelyn Sim has authored 19 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 7 papers in Genetics and 5 papers in Oncology. Recurrent topics in Joycelyn Sim's work include Hematopoietic Stem Cell Transplantation (6 papers), Acute Myeloid Leukemia Research (5 papers) and Multiple Myeloma Research and Treatments (5 papers). Joycelyn Sim is often cited by papers focused on Hematopoietic Stem Cell Transplantation (6 papers), Acute Myeloid Leukemia Research (5 papers) and Multiple Myeloma Research and Treatments (5 papers). Joycelyn Sim collaborates with scholars based in China, Hong Kong and United States. Joycelyn Sim's co-authors include Florent Malard, Xiao‐Jun Huang, Yok‐Lam Kwong, Chor Sang Chim, Eric Tse, Raymond Liang, Chi-Chung Chan, Martin Law, Bonnie Kho and Joyce Chan and has published in prestigious journals such as Blood, CHEST Journal and Leukemia.

In The Last Decade

Joycelyn Sim

16 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joycelyn Sim China 9 199 117 100 57 45 19 292
Alessandra Cupri Italy 11 214 1.1× 88 0.8× 67 0.7× 76 1.3× 50 1.1× 27 313
Elisabetta Calistri Italy 7 205 1.0× 83 0.7× 66 0.7× 111 1.9× 65 1.4× 14 308
Douglas Tremblay United States 10 190 1.0× 179 1.5× 88 0.9× 41 0.7× 47 1.0× 20 328
Kristina Schilling Germany 7 228 1.1× 109 0.9× 55 0.6× 35 0.6× 47 1.0× 14 267
Shin‐ichi Fuchida Japan 11 169 0.8× 44 0.4× 87 0.9× 107 1.9× 55 1.2× 38 294
Bader Alahmari Saudi Arabia 8 209 1.1× 107 0.9× 43 0.4× 75 1.3× 110 2.4× 38 343
Carla Filì Italy 10 310 1.6× 63 0.5× 104 1.0× 52 0.9× 90 2.0× 24 436
Fleur Samantha Benghiat Belgium 11 172 0.9× 180 1.5× 58 0.6× 28 0.5× 178 4.0× 29 435
Kazunori Murai Japan 12 152 0.8× 68 0.6× 93 0.9× 69 1.2× 46 1.0× 48 330
Léonardo Magro France 11 270 1.4× 116 1.0× 75 0.8× 119 2.1× 105 2.3× 43 469

Countries citing papers authored by Joycelyn Sim

Since Specialization
Citations

This map shows the geographic impact of Joycelyn Sim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joycelyn Sim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joycelyn Sim more than expected).

Fields of papers citing papers by Joycelyn Sim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joycelyn Sim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joycelyn Sim. The network helps show where Joycelyn Sim may publish in the future.

Co-authorship network of co-authors of Joycelyn Sim

This figure shows the co-authorship network connecting the top 25 collaborators of Joycelyn Sim. A scholar is included among the top collaborators of Joycelyn Sim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joycelyn Sim. Joycelyn Sim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Lee, Harold, G. Lau, Sze Fai Yip, et al.. (2024). Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM. Bone Marrow Transplantation. 59(5). 660–669.
3.
4.
Morgan, Gareth J., Shaji Kumar, Lisa L. P. Siu, et al.. (2022). The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Therapeutic Advances in Hematology. 13. 1553999803–1553999803. 9 indexed citations
5.
Hwang, Yu‐Yan, Bonnie Kho, June S. M. Lau, et al.. (2022). Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy. Annals of Hematology. 101(6). 1163–1172. 1 indexed citations
6.
Yap, Desmond Y. H., et al.. (2022). Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation. Clinical Kidney Journal. 16(6). 976–984. 5 indexed citations
7.
Leung, Garret M. K., Joycelyn Sim, Yu‐Yan Hwang, et al.. (2021). Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre. Annals of Hematology. 101(1). 155–163. 3 indexed citations
8.
Malard, Florent, Xiao‐Jun Huang, & Joycelyn Sim. (2020). Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 34(5). 1229–1240. 90 indexed citations
9.
Chan, Thomas Y.K., Chor Cheung Tam, Joycelyn Sim, et al.. (2020). PULMONARY VENOOCCLUSIVE DISEASE IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. CHEST Journal. 158(4). A395–A396.
10.
Sim, Joycelyn, Rex Au-Yeung, & Yok‐Lam Kwong. (2019). Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma. Annals of Hematology. 99(2). 385–388. 3 indexed citations
11.
Kwok, Wang Chun, Binmiao Liang, Macy Mei‐Sze Lui, et al.. (2019). Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. Respirology. 24(5). 459–466. 16 indexed citations
12.
Sim, Joycelyn, Cheuk Kwong Lee, Clarence Lam, et al.. (2019). Transfusion of pathogen‐reduced platelet components without leukoreduction. Transfusion. 59(6). 1953–1961. 14 indexed citations
13.
Chim, Chor Sang, et al.. (2014). LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens. European Journal Of Haematology. 94(4). 330–335. 21 indexed citations
14.
Chan, Thomas S. Y., Harinder Gill, Yu‐Yan Hwang, et al.. (2013). Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Annals of Hematology. 93(3). 493–498. 17 indexed citations
15.
Chim, Chor Sang, Sze Fai Yip, Joycelyn Sim, et al.. (2012). Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. Journal of Hematology & Oncology. 5(1). 28–28. 10 indexed citations
16.
Tse, Eric, Anskar Y.H. Leung, Joycelyn Sim, et al.. (2011). Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Annals of Hematology. 90(11). 1277–1281. 13 indexed citations
17.
Chim, Chor Sang, Joycelyn Sim, Chi-Chung Chan, et al.. (2010). Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients. Hematology. 15(4). 187–192. 4 indexed citations
18.
S.K., Edmond, Yuk Wah Chan, Thomas S. K. Wan, et al.. (2009). BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.. PubMed. 15(5). 365–73. 2 indexed citations
19.
Chim, Chor Sang, Yok‐Lam Kwong, Chi-Chung Chan, et al.. (2005). Long-term Outcome of 231 Patients With Essential Thrombocythemia. Archives of Internal Medicine. 165(22). 2651–2651. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandra Cupri Breakdown of academic impact, for papers by Elisabetta Calistri Breakdown of academic impact, for papers by Douglas Tremblay Breakdown of academic impact, for papers by Kristina Schilling Breakdown of academic impact, for papers by Shin‐ichi Fuchida Breakdown of academic impact, for papers by Bader Alahmari Breakdown of academic impact, for papers by Carla Filì Breakdown of academic impact, for papers by Fleur Samantha Benghiat Breakdown of academic impact, for papers by Kazunori Murai Breakdown of academic impact, for papers by Léonardo Magro
Rankless by CCL
2026